Daclatasvir dihydrochloride_1009119-65-6_DataSheet_MedChemExpress
Product Name:
Daclatasvir dihydrochloride CAS No.:
1009119-65-6Cat. No.:
HY-10465MWt:
811.80Formula:
C40H52Cl2N8O6Purity :>98%
Solubility:Mechanisms:
Biological Activity:
References:
Caution: Not fully tested. For research purposes only
Medchemexpress LLC
https://www.wendangku.net/doc/0d3553562.html,
[1]. Fridell RA et al. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro
replicon system. Antimicrob Agents Chemother. 2010 Sep;54(9):3641-50.[2]. Suzuki F, Sezaki H, Akuta N, Suzuki Y, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Arase Y,Ikeda K, Kobayashi M, Mineta R, Watahiki S, Miyakawa Y, Kumada H.Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype
1b.J Clin Virol. 2012 Aug;54(4):352-4. Epub 2012 Jun 1.[3]. Jiang H, Zeng J, Kandoussi H, Liu Y, Wang X, Bifano M, Cojocaru L, Ryan J, Arnold ME.A sensitive and accurate liquid chromatography-tandem mass spectrometry method for quantitative determination of the novel hepatitis C NS5A inhibitor BMS-790052 (daclastasvir) in human plasma and urine.J Chromatogr A.2012 J...
BMS-790052 is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV
replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture.
IC50 Value: 9-50 pM
Target: HCV NS5A BMS-790052 has broad genotype coverage and exhibits picomolar in vitro potency against genotypes 1a (EC50 50pm) and 1b (EC50 9pm). BMS-790052 produces a robust decline in HCV RNA (-3.6 logs after 48hours from a single 100 mg) dosefollowing a single dose in patients chronically infected with HCV genotype 1.
Pathways:Anti-infection; Target:HCV Product Data Sheet
DMSO 56 mg/ml
11 D e e r P a r k D r i v e , S u i t e 102D M o n m o u t h J u n c t i o n , N J 08852,U S A
E m a i l : i n f o @m e d c h e m e x p r e s s .c o m W e b : w w w .m e d c h e m e x p r e s s .c o m